CMN Weekly (13 June 2025) - Your Weekly CRISPR...
CMN Weekly
Jun. 13, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Fate Therapeutics
General information
Main focus: Allogeneic natural killer cell therapies
Company stage: Clinical
Diseases: Acute myleoid leukaemia (AML), B-cell lymphoma (BCL), chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:FATE)
Location: San Diego, CA, USA
Website: https://fatetherapeutics.com/
Pipeline: https://fatetherapeutics.com/pipeline/
Partners: Janssen Pharmaceuticals, Ono Pharma, Inscripta
Fate Therapeutics is a publicly-traded, clinical-stage, biopharmaceutical company mainly focusing on the development of first-in-class cellular immunotherapies. The company applies an in house iPSC and gene-editing platform to develop T- and natural killer cell therapies targeting blood cancers and solid tumours.
